Guided by reports that anti-VEGF therapy increases hypoxia within viable tumor areas (Franco et al., 2006; Shi et al., 2017) and that low oxygen bioavailability enhances the cytotoxic function of CD8 T cells (de Almeida et al., 2020; Doedens et al., 2013), we found increased tumor hypoxia and accumulation of CD8 T cells within hypoxic regions (Figures 2I and 2J). Here, VEGFA is linked to neoplasm.